

Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

Information for the public

Published: 14 December 2022

www.nice.org.uk

Amivantamab (Rybrevant) is not normally available on the NHS for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [EGFR Positive UK](https://www.egfrpositive.org.uk), contact@egfrpositive.org.uk
- [Roy Castle Lung Cancer Foundation](https://www.roycastle.org.uk), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](https://www.lcnuk.org), 01675 477 607
- [Cancer Research UK](https://www.cancerresearchuk.org), 0808 800 4040
- [Macmillan Cancer Support](https://www.macmillan.org.uk), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4857-4